Pharmaceuticals
Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease
PANGYO, South Korea, Sept. 14, 2023 /PRNewswire/ -- Oscotec Inc. and ADEL Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application of ADEL-Y01 for the treatment of Alzheimer's disease (AD). Oscotec and ADEL are jointly developing ...
2023-09-14 20:00
1260
Porton Advanced and BRL Medicine Build Strategic Partnership to Accelerate Commercialization of Gene and Cell Therapies
SUZHOU, China, Sept. 14, 2023 /PRNewswire/ -- On September 13th, 2023, Porton Advanced Solutions (Porton Advanced) announced a strategic partnership with BRL Medicine Inc. (BRL Medicine). This collaboration will enhance the cell and gene therapy pipelines from BRL Medicine from clinical trials to...
2023-09-14 20:00
1510
Foundry Mixer Healthcare, Indonesian Minister of Health Budi G. Sadikin: "Together We Leapfrog Indonesia's Healthcare Transformation"
Indonesian Minister of Health, Budi Gunadi Sadikin, emphasized that investing in the Health Technology and Biotechnology sector serves not only business prospects but also strengthens Indonesia's health resilience and adds value to healthcare. JAKARTA, Indonesia, Sept. 14, 2023 /PRNewswire/ -- F...
2023-09-14 17:47
1425
Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL
SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Dizal today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for golidocitinib for the treatment of relapsed or refractory peripheral T-cell lymphom...
2023-09-14 17:07
1186
Asieris' New Drug APL-1401 Completes First Administration in Patient with Moderately to Severely Active UC
SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its oral drug APL-1401 for the tr...
2023-09-14 16:54
1295
Nona Biosciences Expands Antibody Discovery Collaboration with BeiGene
CAMBRIDGE, Mass., Sept. 14, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting edge antibody technology innovation and provider of integrated antibody discovery and development solutions from "Idea to IND" (I to I™), announced an agreeme...
2023-09-14 16:00
1251
Innovative Collaboration: Buzzreach and Oncoshot Spearhead Clinical Trial Advancements in Japan
SINGAPORE, Sept. 14, 2023 /PRNewswire/ -- Buzzreach and Oncoshot, two prominent entities in the clinical trials domain, have announced an impactful collaboration to accelerate clinical trials inJapan. The former specialises in clinical trial site recruitment and retention and project managemen...
2023-09-14 10:00
1945
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
— ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine's artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models — — In May 2023, the U.S. Food and Drug Administration (FDA) cleared Insilico's I...
2023-09-13 20:29
1585
J INTS BIO, WCLC 2023 - Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI
SEOUL, South Korea, Sept. 13, 2023 /PRNewswire/ -- J INTS BIO announced that Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' was presented at the 2023 IASLC World Conference on Lung Cancer held inSingapore from 9th to 12th September, during the official session...
2023-09-13 15:58
1426
Zuberitamab (Anruixi®), the first domestically developed anti-CD20 antibody as a Class I innovative drug from BioRay Pharmaceutical, has been approved for marketing in China
SHANGHAI, Sept. 13, 2023 /PRNewswire/ -- Recently, BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as "Bioray") announced that its independently developed Class I innovative therapeutic biological product, Zuberitamab Injection (trade name: Anruixi®), indicated for the treatment of CD20...
2023-09-13 14:24
1237
Caliway Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of Over 50% and Reduced Pain by 4.7
- CBL-0201DD Phase 2 study met the primary and all secondary endpoints. - 64.5% of painful lipomas showed complete clearance or dimensions reduction of more than 50% after CBL-514 treatments. - 54.8% of painful lipomas showed complete clearance or dimension reduction of more th...
2023-09-13 13:42
1155
Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets
SINGAPORE, Sept. 13, 2023 /PRNewswire/ -- Menarini Asia-Pacific has entered into a long-term exclusive licensing partnership with Astellas Pharma Inc. (Astellas) for the development, manufacturing and commercialization of the orally administered Janus kinase (JAK) inhibitor Smyraf® 50 mg and 100 ...
2023-09-13 10:30
2146
GemPharmatech's Board Appoints Brandy Wilkinson, Ph.D. as its New Chief Executive Officer of GemPharmatech LLC.
SAN DIEGO, Sept. 12, 2023 /PRNewswire/ -- GemPharmatech LLC., a leading
contract research organization, announced today that its Board of Directors has
appointed Dr.Brandy Wilkinson as the Chief Executive Officer of its subsidiary
inthe United States, effective September 12, 2023.
2023-09-13 00:00
1296
Pierre Fabre Laboratories Acquires Vertical Bio and its Innovative Targeted Therapy Candidate for Patients Suffering From Non-Small Cell Lung Cancer With MET Alteration
CASTRES, France and BASEL, Switzerland, Sept. 12, 2023 /PRNewswire/ --
Pierre Fabre Laboratories
2023-09-12 20:00
1250
Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA
* HANSIZHUANG's coverage footprint includes 22 emerging market countries acrossSoutheast Asia and MENA – * KGbio to develop and commercialise HANSIZHUANG in 12 MENA countries; Henlius to receiveUS$7 million upfront payment plus royalties and up to US$8 million in regulatory milestone payments...
2023-09-12 19:24
1227
IPMG Drives Health Transformation and Strengthens Indonesia's Economy Through Efforts to Accelerate Access to Innovative Medicines and Vaccines, also Partnerships
JAKARTA, Indonesia, Sept. 11, 2023 /PRNewswire/ -- The research and development-based multinational pharmaceutical industry association, the International Pharmaceutical Manufacturers Group (IPMG) is always committed to supporting and encouraging advocacy and transformation of Government policie...
2023-09-11 18:52
1803
Norgine Strengthens Senior Leadership with the Appointment of Saulo Martiniano as Chief Operating Officer
AMSTERDAM, Sept. 11, 2023 /PRNewswire/ -- Norgine, a leading European specialist pharmaceutical company dedicated to improving the lives of patients, is pleased to announce the appointment ofSaulo Martiniano as its new Chief Operating Officer (COO). Saulo joins Norgine with a wealth of experience...
2023-09-11 15:00
1036
Norgine Strengthens Senior Leadership with the Appointment of Saulo Martiniano as Chief Operating Officer
AMSTERDAM, Sept. 11, 2023 /PRNewswire/ -- Norgine, a leading European specialist pharmaceutical company dedicated to improving the lives of patients, is pleased to announce the appointment ofSaulo Martiniano as its new Chief Operating Officer (COO). Saulo joins Norgine with a wealth of experience...
2023-09-11 15:00
1106
Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors
SINGAPORE, Sept. 11, 2023 /PRNewswire/ -- On September 9th, 2023, Biosyngen Pte Ltd (hereafter as "Biosyngen") announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for Phase I/II clinical trial ofBRL03 for the treatment of lung cancer, gastric cancer and other ad...
2023-09-11 14:53
1124
Nobel Trust Family Joins BIOHK2023 - Unveiling Key Announcement
HONG KONG, Sept. 8, 2023 /PRNewswire/ -- BIOHK2023 garnered widespread acclaim featuring an exceptional lineup of speakers, including aNobel Laureate, world-renowned scientists who have won distinguished awards, and accomplished biotech C-level venture capitalists taking the stage on 13th to 16th...
2023-09-08 16:30
2163
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 281 media titles]
2024-04-18 21:26
Animated Life in Yunnan
[Picked up by 278 media titles]
2024-04-18 14:00
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 276 media titles]
2024-04-19 13:25
Most Read
Sephora appoints Xia Ding as Managing Director of Sephora Greater China
2024-04-15 17:33
3817
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
2024-04-15 08:00
3083
Goldpac Exhibits at InnoEx 2024
2024-04-13 10:00
3003
